RH5.1/Matrix-M malaria vaccine

RH5.1 antigen with Matrix-M adjuvant · University of Oxford (sponsor); Matrix-M adjuvant developed by Novavax

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RH5.1/Matrix-M malaria vaccine, covering 2024-11-22 to 2024-11-22. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania [Phase 1]